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A B S T R A C T   
The majority of cellular energy is produced by the mitochondrial oxidative phosphorylation (OXPHOS) system. 
Failure of the first OXPHOS enzyme complex, NADH:ubiquinone oxidoreductase or complex I (CI), is associated 
with multiple signs and symptoms presenting at variable ages of onset. There is no approved drug treatment yet 
to slow or reverse the progression of CI-deficient disorders. Here, we present a comprehensive human metabolic 
network model of genetically characterized CI-deficient patient-derived fibroblasts. Model calculations predicted 
that increased cholesterol production, export, and utilization can counterbalance the surplus of reducing 
equivalents in patient-derived fibroblasts, as these pathways consume considerable amounts of NAD(P)H. We 
show that fibrates attenuated increased NAD(P)H levels and improved CI-deficient fibroblast growth by stimu-
lating the production of cholesterol via enhancement of its cellular efflux. In CI-deficient (Ndufs4− /− ) mice, 
fibrate treatment resulted in prolonged survival and improved motor function, which was accompanied by an 
increased cholesterol efflux from peritoneal macrophages. Our results shine a new light on the use of compen-
satory biological pathways in mitochondrial dysfunction, which may lead to novel therapeutic interventions for 
mitochondrial diseases for which currently no cure exists.  
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1. Introduction 
ATP, the main cellular energy source, is predominantly produced by 
the mitochondrial oxidative phosphorylation (OXPHOS) system, which 
consists of five enzyme complexes and two electron carriers. OXPHOS 
dysfunction is the primary cause of many inherited mitochondrial dis-
orders and has been associated with more common diseases, including 
cancer, heart failure and neurodegeneration [1–4]. Complex I (CI) is the 
most frequently affected OXPHOS complex. A deficient activity of this 
complex is the underlying cause of many mitochondrial disorders, 
including Leigh syndrome [5,6]. The often early fatal disease typically 
manifests within the first two years of life and is characterized by 
elevated blood and cerebrospinal fluid lactate concentrations. At the 
cellar level ATP production is reduced and reactive oxygen species 
(ROS) and NAD(P)H levels are increased [6]. Suitable treatment options 
remain enigmatic. 
The detrimental effect of high NAD(P)H levels on cell growth and 
respiratory capacity was recently illustrated using various genetically- 
encoded strategies [7,8,9], and was emphasized by its association with 
cytosolic ROS production by NADPH oxidases [10,11]. Increased mito-
chondrial NAD(P)H concentrations in CI-deficient cells are probably due 
to reduced NADH oxidation. This is supported by the negative correla-
tion between residual CI activity and NAD(P)H autofluorescence found 
in a large panel of CI-deficient patient fibroblasts [6,12], and the 
decreased NAD+ levels that paralleled NADH increase in CI-deficient 
mouse embryonic fibroblasts [13]. NADH could increase cytosolic 
NADPH levels through the isocitrate/α-ketoglutarate shuttle (Fig. 1A). 
More recently, proline biosynthesis demonstrated to act as a compen-
satory mechanism to decrease mitochondrial redox stress, by attenua-
tion of cellular NADH levels [14]. This gives rise to the concept that the 
flexible nature of cellular metabolic pathways can compensate for the 
high NAD(P)H levels in CI deficiency. 
Here, we used metabolic network modeling to explore such 
compensatory pathways. The model predicted potentially novel thera-
peutic targets to lower elevated cellular NAD(P)H levels by stimulating 
NADPH-consuming cholesterol biosynthesis via enhancement of 
cholesterol export. In vitro and in vivo studies revealed that fibrate 
treatment restored NAD(P)H levels and growth rates in CI-deficient 
patient-derived fibroblasts, and prolonged survival and improved 
motor function in CI-deficient mice, respectively. Further studies are 
warranted to evaluate the clinical potential of our findings as a novel 
option to ameliorate or reverse CI-deficient disease progression. 
2. Materials and methods 
2.1. Model pre-processing 
In this study we used the constraint-based model of human meta-
bolism by Duarte et al. [15], which comprises 2766 metabolites, 3742 
reactions and 1905 genes. We identified 9 pairs of reactions with 
matching stoichiometries but differing reversibilities, and deleted the 
irreversible member of these pairs (cf [16]). Metabolic models were 
constrained by mimicking the in vitro nutrient condition from which the 
gene expression profiles were determined (Supplementary Table C.1) To 
obtain a gapless model, necessary for our EXploration of Alternative 
Metabolic Optima (EXAMO) [17] analysis, we identified and deleted 
blocked reactions using Flux Variability Analysis [18]. The resulting 
gapless model comprised 1379 metabolites, 2128 reactions, and 1415 
genes, and was used for all modeling studies. All linear equations were 
solved using IBM’s CPLEX optimization toolbox 12.5. 
2.2. EXploration of Alternative Metabolic Optima (EXAMO) 
We used EXAMO to predict reactions that are likely to be active in 
control or patient skin fibroblasts. In addition to a gapless constraint- 
based metabolic model, EXAMO requires a list of highly and lowly 
expressed metabolic genes. Both for patient and control fibroblasts of 
each age- and sex-matched pairs, gene expression data of the CI- 
deficient patient and control fibroblasts have been published previ-
ously [19] (GSE27041). We ranked the genes according to their 
expression level and classified the top 15% as ‘highly expressed’ and 
bottom 15% as ‘lowly expressed’. The EXAMO algorithm is described 
elsewhere [17]. Briefly, using the information on highly and lowly 
expressed genes and the metabolic model’s detailed Boolean gene-to- 
reaction mapping, EXAMO defines sets of highly and lowly expressed 
reactions. Next, EXAMO solves and explores the alternative optima of a 
mixed integer linear program that maximizes agreement between gene 
expression and metabolic fluxes. More precisely, EXAMO finds flux 
distributions that maximize the sum of the number of highly expressed 
reactions carrying flux and the number of lowly expressed reactions that 
do not carry flux. Counting the number of times that a reaction in 
question is active in the alternative optimal solutions provides a measure 
for the likelihood that the reaction is indeed active. Reactions active in 
all alternative solutions are called ‘high-frequency reactions’ (HFRs) and 
are predicted to be active in the condition of interest. Reactions that are 
inactive in all optimal solutions are called ‘zero-frequency reactions’ 
(ZFRs) and are predicted to be inactive in the actual cells. EXAMO 
yielded 27 ZFRs for C6855 and 27 other ZFRs for P6613. With respect to 
HFRs, these numbers were 447 and 556 for C6855 and P6613, respec-
tively (Supplementary Tables D.1 and E.1). Essentially the same results 
were obtained with the patient and control fibroblasts of the other age- 
and sex-matched pairs. 
2.3. Cell culture 
Primary skin fibroblasts of healthy subjects and CI-deficient patients 
were derived from skin biopsies in accordance with the applicable rules 
concerning the review of research ethics committees (Commissie 
Mensgebonden Onderzoek Regio Arnhem-Nijmegen). Primary skin fi-
broblasts were maintained in medium M199 containing 5.5 mM glucose 
and 25 mM HEPES (Life Technologies), supplemented with 10% (v/v) 
fetal bovine serum (FBS, MP Biomedicals) at 37 ◦C in a humidified at-
mosphere of 5% (v/v) CO2. HeLa cells (American Type Culture Collec-
tion, CCL-2) were maintained at 37 ◦C in a humidified atmosphere of 5% 
(v/v) CO2 in Dulbecco’s Modified Eagle’s medium (DMEM) containing 
25 mM glucose, GlutaMAX™, 1 mM pyruvate (Gibco™ Life Technolo-
gies, 31966) supplemented with 10% (v/v) FBS. All cells were regularly 
tested for mycoplasma contamination. 
2.4. Staining of cellular cholesterol by Filipin III 
Primary skin fibroblasts (1000 cells per chamber) were seeded on 8- 
chamber glass slides (Nunc™ Lab-Tek™ II Chamber Slide™ System, 
Thermo Scientific) 24 h prior to exposure. After a 24-hour exposure to 
gemfibrozil, cells were fixed in 3% (m/v) paraformaldehyde and 2% 
glutaraldehyde (v/v) in PBS for 1 h in the dark. Next, cellular cholesterol 
was stained with Filipin III (5% (m/v) in dimethylformamide and PBS, 
1:50 (v/v), Sigma Aldrich) for 1 h in the dark. Images were obtained 
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using an Olympus FV1000 confocal laser scanning microscope 
(Olympus) equipped with Olympus software FV10-ASW version 1.7. 
2.5. Measurement of cellular cholesterol levels 
Primary skin fibroblasts (1.0 ⋅ 105 cells) were seeded 24 h prior to 
determination of cellular cholesterol levels. Cells were harvested and 
total cholesterol was measured using the Amplex® Red Cholesterol 
Assay Kit, according to manufacturer’s instruction, with the addition of 
cholesterol esterase, to measure both free and esterified cholesterol (Life 
Technologies). Cholesterol content was normalized to mg protein in the 
cell lysate as determined by a Biorad protein assay (Biorad). 
2.6. Cholesterol efflux measurements 
HeLa cells were seeded (13000 cells⋅well− 1) in DMEM (Sigma 
Aldrich, D4947) supplemented with 10% (v/v) dialyzed FBS. After a 24- 
hour incubation, the cells were treated with compound in DMEM (Sigma 
Aldrich, D4947) supplemented with 0.2% (m/v) low endotoxin, essen-
tially fatty-acid free bovine serum albumin (BSA). The medium was 
replaced with DMEM (Sigma Aldrich, D4947) supplemented with 0.2% 
(m/v) BSA containing 1 μCi [3H]-cholesterol and compound in the 
absence or presence of 1 μM piericidin A (PA). After 24 h of cholesterol 
loading, the cells were washed twice with medium supplemented with 
0.2% (m/v) BSA. Subsequently, the medium was replaced with medium 
supplemented with 0.2% (m/v) BSA in the absence or presence of 10 
μg⋅mL− 1 of the acceptor molecule apolipoprotein (apo) A-I. Resident 
peritoneal macrophages were isolated by washing the peritoneal cavity 
twice with 2.5 mL RPMI 1640 medium supplemented with 10 U⋅mL− 1 
heparin and 2% (v/v) FBS. Cells were counted, resuspended, and seeded 
in 96-well plates at a density of 1.5 ⋅ 106 cells⋅well− 1, and incubated at 
37 ◦C in a humidified atmosphere of 5% (v/v) CO2. Four hours after 
seeding, non-adherent cells were removed. Cholesterol efflux was 
determined according to a previously described method with slight 
modifications [20]. After 24-hour incubation, macrophages were loaded 
with 1 μCi [3H]-cholesterol (Perkin Elmer) in RPMI 1640 medium sup-
plemented with 0.2% (m/v) BSA. Next, cells were washed twice with 
RPMI 1640 medium supplemented with 0.2% (m/v) BSA and subse-
quently cholesterol efflux was allowed to equilibrate for 30 min. The 
medium was replaced with RPMI 1640 medium supplemented with 
0.2% (m/v) BSA with or without apoA-I (10 μg⋅well− 1, Merck Millipore). 
From this step on, the procedure was the same for both cell types. 
Cholesterol efflux was allowed to proceed for 4 h. Afterwards, we 
collected the medium and resuspended in scintillant. Cells were lysed by 
the addition of 0.1% (m/v) NaOH for 10 min, and also resuspended in 
scintillant. Samples were quantified using a scintillation counter (Perkin 
Elmer Tri Carb 2900TR, Perkin Elmer) and cholesterol efflux was 
calculated as percentage of radioactivity measured in the medium over 
total radioactivity (medium plus cells). 
2.7. Cholesterol biosynthesis flux analysis 
Cholesterol biosynthesis flux in HeLa cells upon lovastatin and 
gemfibrozil exposure was determined as described previously [21,22]. 
Briefly, HeLa cells were cultured at a density of 166000 cells⋅well− 1 in 
DMEM (Sigma Aldrich, D4947) supplemented with 10% (v/v) dialyzed 
FBS. After 24 h, cells were washed with serum-free DMEM and incu-
bated with 5 μM lovastatin, 100 μM gemfibrozil or 0.1% (v/v) DMSO as 
vehicle control in serum-free DMEM for 21 h. Cells were exposed to 1 
μCi⋅mL− 1 14C-acetic acid sodium salt (Perkin Elmer) with either 5 μM 
lovastatin, 100 μM gemfibrozil or 0.1% (v/v) DMSO as vehicle control 
for 3 h, followed by washing twice in PBS. Medium and PBS were 
collected to determine extracellular cholesterol levels. To extract 
cholesterol lipids, plates were, covered in parafilm, incubated with 1 mL 
hexane:isopropanol (3:2, v/v). After 3 h, medium was collected and 
evaporated under nitrogen stream. Dried samples were resuspended in 
chloroform:methanol (3:1, v/v), nitrogen-dried and resuspended in 20 
μL chloroform:methanol (3:1, v/v). 20 μL of medium and cellular sam-
ples and 5 mg⋅mL− 1 cholesterol standard (Sigma Aldrich) were applied 
to a TLC silica gel 60 F254 plate (Millipore). Once air-dried, TLC plates 
were run in 100% chloroform for 20 min and developed with iodine 
vapor (Iodine beads, Sigma Aldrich). Cholesterol spots were scratched 
from the plates and mixed with 4 mL Opti-Fluor (Perkin Elmer). 14C- 
labelled cholesterol was quantified by a liquid scintillation counter 
(Hidex SL 600, Hidex). Cells were imaged using Leica DM-IL equipped 
with a 10× objective and manually counted in ImageJ, version 2.0.0-rc- 
49/1.51d, and used to corrected radioactive counts for cell number. 
2.8. Analysis of mitochondrial oxygen consumption 
To determine fatty acid-driven mitochondrial oxygen consumption, 
1.0 ⋅ 106 human skin fibroblasts were resuspended in mitochondrial 
Fig. 1. CI-deficient fibroblasts increase cholesterol biosynthesis to compensate for increased cellular NAD(P)H levels. (A) Schematic representation of the transfer of 
reducing equivalents of mitochondrial NADH to cytosolic NADPH, based on the model-predicted involvement of the cytosolic isocitrate dehydrogenase (IDH1) in CI 
deficiency, and the routes by which increased NADH levels contribute to cell death pathways, including damaging reductive stress and mitochondrial permeability 
transition (MPT). (B) Model-predicted patient-specific metabolic reactions, classified according to Recon1 pathway classes and displayed as a fraction of all patient- 
specific metabolic reactions. (C) Model-predicted reactions of the cholesterol (derivative) biosynthesis pathway using electrons through cytosolic NADPH. (D) 
Cellular NAD(P)H levels were determined after treatment for 24 h with lovastatin hydroxyacid (5 μM) in patient and healthy control fibroblasts (n ≥ 81 individual 
cells analyzed in n = 3 independent experiments). (E) Lovastatin-induced increase in NAD(P)H levels in control and patient fibroblasts. (F) NAD(P)H levels were 
determined after treatment for 48 h with lovastatin hydroxyacid (5 μM) in CI-inhibited (i.e. using piericidin A, 1 μM) HeLa cells (n ≥ 160 individual cells analyzed in 
n = 3 independent experiments). (G) Lovastatin-induced changes in NAD(P)H levels in HeLa cells with and without piericidin A-induced CI inhibition. (H–I) Filipin 
III-staining to visualize cellular cholesterol in (H) control and (I) CI-deficient patient fibroblasts. Scale bars, 50 μm. (J) Biochemical determination of cellular 
cholesterol in these fibroblasts. Data are presented as means ± SEM. (D, F) ###p < 0.001 to compare genotype or treatment vs vehicle differences or **p < 0.01, ***p 
< 0.001 to compare treatment effects, by two-way ANOVA (G: genotype; I: inhibitor (i.e. piericidin A); T: treatment; T*I: treatment*inhibitor interaction) with 
Bonferroni’s post hoc analysis. (E, G, J). **p < 0.01, ***p < 0.001, ns, not significant, by independent Student’s t-test. 
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respiratory medium (MiR05), before being transferred to the chamber of 
an Oxygraph-2k (Oroboros) and allowed to reach a stable basal oxygen 
consumption rate for 10 min. After digitonin permeabilization (10 μg/1 
⋅ 106 cells, Sigma Aldrich) of the cell membrane, 4 mM butyric acid 
(Sigma Aldrich), 20 μM palmitoyl-L-carnitine (Sigma Aldrich), and 2 mM 
malate (Sigma Aldrich) were added to stimulate fatty acid oxidation 
(STATE4). Finally, maximal ADP-stimulated (STATE3) oxygen con-
sumption was determined by the addition of 4 mM ADP (Sigma Aldrich). 
Muscle fibers were freshly isolated from M. quadriceps femoris as 
described previously [23], permeabilized by saponin (50 μg⋅mL− 1) 
treatment at 4 ◦C for 20 min, and thoroughly washed in respiration 
medium MiR05. Muscle fiber wet weight was determined and ~8 mg of 
muscle fibers was transferred to each of the chambers of the Oxygraph-2 
k. Palmitoyl-L-carnitine (20 μM, Sigma Aldrich), 4 mM ADP (Sigma 
Aldrich) and 4 mM malate (Sigma Aldrich) were added to stimulate fatty 
acid oxidation (STATE4). Finally, maximal ADP-stimulated (STATE3) 
oxygen consumption was determined by the addition of 4 mM ADP 
[23,24]. Rotenone (0.5 μM, Sigma Aldrich), and antimycin A (2.5 μM, 
Sigma Aldrich) were added to inhibit CI and CIII, respectively, and to 
determine non-mitochondrial respiration. These levels were subtracted 
from all other respiratory rates. Cytochrome c (10 μM, Sigma Aldrich) 
was added to check the integrity of the mitochondrial outer membrane. 
2.9. Measurement of cellular NAD(P)H autofluorescence 
For quantitative determination of cellular NAD(P)H auto-
fluorescence, human primary skin fibroblasts (5.0 ⋅ 104 cells) were 
seeded in 35 mm Fluorodishes (World Precision Instruments), 24 h prior 
to compound exposure. After exposure, the medium was replaced by 
HEPES-Tris (HT) buffer (132 mM NaCl, 4.2 mM KCl, 5.5 mM D-glucose, 
1 mM MgCl2, 1 mM CaCl2 and 10 mM HEPES, pH 7.4) and images were 
obtained using a temperature-controlled chamber attached to a stage of 
an inverted microscope (Axiovert 200M, Carl Zeiss) equipped with a 
×40, 1.25 NA Plan NeoFluar oil immersion objective, as described 
previously [25]. The cells were excited at 360 nm for 1000 ms using a 
monochromator (Polychrome IV, TILL Photonics). Fluorescence emis-
sion light was directed by a 415DCLP dichroic mirror (Omega Optical 
Inc.) through a 510WB40 emission filter (Omega Optical Inc.) onto a 
CoolSNAP HQ monochrome CCD-camera (Roper Scientific). A similar 
procedure was used for NAD(P)H quantification in HeLa cells. Briefly, 
HeLa cells were seeded at a density of 10000 cells in DMEM containing 
1 g⋅L− 1 glucose (Sigma-Aldrich, D4947) supplemented with 10% (v/v) 
dialyzed FBS and incubated overnight. Next, the compounds were added 
as described above. After 24 h, the medium was replaced with medium 
containing compounds in the presence or absence of 1 μM piericidin A. 
After another 24-hour incubation, medium was replaced by HT buffer 
for image acquisition. Images were recorded as described above for the 
human primary skin fibroblasts. After background subtraction, average 
cellular intensity was determined using Image Pro Plus 6.0.0.260 soft-
ware (Media Cybernetics) to determine NAD(P)H levels. 
2.10. Catalytic capacity of individual OXPHOS complexes 
Primary skin fibroblast pellets were snap frozen in liquid nitrogen, 
and kept at − 80 ◦C until use. Cell pellets were resuspended in 10 mM 
Tris-HCl and pottered, followed by the addition of sucrose (215 mM). 
The lysate was cleared of unbroken cells by centrifugation (10 min, 
600g), after which the supernatant containing mitochondria was pel-
leted at 14000g for 10 min, resuspended in 10 mM Tris-HCl (pH 7.6) and 
snap frozen in aliquots. Catalytic capacity of OXPHOS complexes was 
measured spectrophotometrically in duplicate, as described previously 
[26]. Briefly, the following substrates were used: NADH (0.2 mM, 
Roche) and coenzyme Q1 (70 μM, Sigma Aldrich) for CI; succinate (10 
mM, Sigma Aldrich) and decylubiquinone (80 μM, Enzo Life Sciences) 
for CII; decylubiquinol (300 μM, Enzo Life Sciences) and cytochrome c 
(50 μM, Sigma Aldrich) for CIII; reduced cytochrome c (70 μM, Sigma 
Aldrich) for CIV; and ATP (3 mM, Sigma Aldrich) for CV. For the 
determination of the ATPase activity of CV, 10 μM oligomycin was used 
to correct for non-CV ATPase activity. CI-CV values were normalized to 
the activity of the mitochondrial matrix enzyme, citrate synthase, to 
correct for differences in mitochondrial mass. Citrate synthase was 
determined spectrophotometrically in duplicate as described before 
[26]. 
2.11. Analysis of mitochondrial area 
Human skin fibroblasts (5.0 ⋅ 104 cells) were seeded in 35 mm Flu-
orodishes (World Precision Instruments), 24 h prior to gemfibrozil (100 
μM) exposure. To determine the mitochondrial area, cells were loaded 
with 100 nM tetramethylrhodamine methyl ester (TMRM) for 25 min at 
37 ◦C, as described previously [27]. Subsequently, images were obtained 
using a temperature-controlled chamber attached to a stage of an 
inverted microscope (Axiovert 200 M, Carl Zeiss) equipped with a ×63, 
1.25 NA Plan NeoFluar oil immersion objective. Cells were maintained 
in HT buffer for image acquisition. Image analysis consisted of sub-
traction of background intensity, after which images were masked with 
a binarized image for mitochondrial morphology using Image Pro Plus 
6.3 software (Media Cybernetics). 
2.12. Growth curve construction 
Twenty-four hours prior to gemfibrozil exposure, primary skin fi-
broblasts were seeded in 96-wells black/clear imaging plates (Santa 
Cruz Biotechnology) at a density of 1000 cells/well in DMEM medium 
supplemented with 10% (v/v) FBS). A 1000× concentrated serial √10- 
dilution of gemfibrozil was made in DMSO. Immediately before use, this 
gemfibrozil stock solution was diluted 100× in PBS, and 10× in culture 
medium, resulting in a final DMSO concentration of 0.1% (v/v). Three 
replicates of each concentration were tested up to a maximum concen-
tration of 100 μM. After 24-hour exposure, nuclei were stained using 
Hoechst 33342 (20 μg⋅mL− 1, Life Technologies) for 20 min at 37 ◦C. 
Fluorescence was imaged on a BD Pathway 855 high-throughput mi-
croscope (Becton Dickinson (BD) Bioscience). The number of nuclei per 
image was analyzed using CellProfiler [28]. Linear regression analysis of 
the natural log-transformed exponential part of the growth curves was 
performed and the doubling time was calculated from the inverse slope 
of the linear fit. 
2.13. Mice 
Initial breeding pairs of heterozygous Ndufs4+/− mice (mixed 129/ 
Sv: C57BL6 background) [29,30] were kindly provided by the Palmiter 
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laboratory (University of Washington, Seattle) and sustained in our 
(specific pathogen free) breeding facility. Ndufs4+/− mice were inter-
crossed to produce Ndufs4− /− mice. All mice were group-housed under 
controlled conditions (temperature 20–22 ◦C, humidity 50–70%) with 
free access to standard food (V1534–300 R/M-H from Ssniff GmbH, 
Soest, Germany)) and water and maintained on a 12-hour light/dark 
cycle (lights on at 7 am), as described previously [31]. Pups received toe 
tattoos for identification and tail clips were taken for genotyping at PD 8. 
Then wildtype and Ndufs4− /− mice were assigned to each treatment 
group using manual randomization. Randomization of housing condi-
tions was performed by manual randomization of the cage location 
within the animal room (rack/shelf). Administration of treatments and 
result assessment were performed blinded. Sample sizes and power 
calculations were bases on previous studies using the Ndufs4− /− mice by 
ourselves and others [31,32]. Experiments part of this study (incl. 
sampling, outcome assessment, analysis) were performed blinded. Ani-
mal caretakers and researchers were also blinded during day-to-day 
animal care concerning treatment group. Both female and male 
Ndufs4− /− and wildtype mice were treated via intraperitoneal injection 
with 100 mg⋅kg bodyweight− 1⋅day− 1 fenofibric acid (n = 8 wildtype, n 
= 8 Ndufs4− /− , Sigma Aldrich) or vehicle (n = 13 wildtype, n = 10 
Ndufs4− /− , 0.9% (m/v) NaCl solution), from PD 20 onwards. All mice 
were weaned at the age of postnatal day (PD) 24. Ndufs4− /− mice were 
always housed with a minimum of one wildtype littermate for warmth 
and provided with food on the bottom of the cage. Mice were weighed 
daily and clinical symptoms were observed. Based on ethical consider-
ations and regulations it should be stated that no permission was ob-
tained to pass the so-called humane endpoint, indicated by the severity 
of clinical symptoms observed in combination with a body weight loss of 
>20%. Ethical approval was obtained by the Committee for Animal Care 
and Experimental Use of the Radboud University Medical Center Nij-
megen, The Netherlands (ref. no. 2013-210 and 2017-0017). Experi-
ments were carried out in agreement with the Dutch laws, ARRIVE 
guidelines and the European Communities Council Directive (2010/63/ 
EU). 
2.14. Motor function assessment 
Motor function was assessed using the CatWalk system (Noldus), 
which is an automated gait analysis system to objectively assess motor 
function in rodents and previously used for the Ndufs4− /− mice [31,32]. 
At PD 27 and PD 28, mice were habituated to the CatWalk with their 
cage mates for 10 min. Testing was performed individually in the dark, 
starting at PD 30. A walking session was successful after completing 
three compliant runs. A compliant run meets the run criteria set at a 
maximum run duration of 10 s. 
2.15. ALAT and ASAT determination 
Plasma alanine aminotransferase (ALAT) and aspartate aminotrans-
ferase (ASAT) levels were determined biochemically, as previously 
described [33]. Briefly, the samples were diluted 1:20 in either ALAT 
reaction solution (100 mM tris(hydroxymethyl)aminomethane, 500 
mM L-alanine, 0.18 mM NADH, 0.1 mM pyridoxal-5′- phosphate, 1700 
U⋅L− 1 lactate dehydrogenase, pH 7.15) or ASAT reaction solution (80 
mM tris(hydroxymethyl)aminomethane, 240 mM L-aspartate, 0.18 mM 
NADH, 0.1 mM pyridoxal-5′- phosphate, 600 U⋅L− 1 malate dehydroge-
nase, 900 U⋅L− 1 lactate dehydrogenase, pH 7.65). To start the ALAT or 
ASAT measurements, 15 mM or 12 mM 2-oxoglutaric acid was added to 
the sample, respectively. Finally, the absorbance at 340 nm was 
measured using a Biorad Benchmark Plus spectrophotometer for 10 min 
at 37 ◦C (Biorad Laboratories). The enzyme activity was derived from 
the linear range of the curve. 
2.16. Hepatic lipid quantification 
Liver samples (25 mg) were resuspended in 1 mL ice-cold iso-
propanol (Merck) to isolate lipids. The liver samples were homogenized 
by tissue grinding and sonication for 20 min in ice water. After centri-
fugation, the supernatant containing the lipids was evaporated at 65 ◦C. 
The residual lipid pellet was resuspended in isopropanol and stored at 
− 20 ◦C until quantification. Lipid quantification was performed by 
spectrophotometric sulfo-phospho-vanillin assessment as previously 
described, with minor modifications [34]. Briefly, samples were diluted 
1:1 in isopropanol and incubated at 90 ◦C for 30 min to evaporate all 
organic solvents. The pellets were resuspended in 95% (m/v) sulphuric 
acid (Merck) and incubated at 90 ◦C for 20 min. Next, the samples were 
rapidly cooled for 5 min at 4 ◦C. Pre-vanillin absorbance levels were 
determined using a Biorad Benchmark Plus spectrophotometer at 535 
nm (A535). Then, 0.2 mg⋅mL− 1 vanillin (Sigma Aldrich) in 17% (v/v) 
aqueous phosphoric acid (Merck) was added to the samples (1:2 ratio). 
After a 10-minute light protected incubation at room temperature, post- 
vanillin absorbance levels were determined (A535). Lipid levels were 
defined as the difference between pre-vanillin and post-vanillin absor-
bance levels. Vehicle-treated wildtype mice were set at 100% to 
compare lipid levels in liver samples. 
2.17. Histology 
Livers were dissected and post-fixed overnight with 4% (v/v) form-
aldehyde, and subsequently embedded in paraffin. Liver slices of 5 μm 
were obtained and stained with Mayer’s hematoxylin for 3 min. Sub-
sequently, sections were washed (water 5 min, 1% (m/v) NaHCO3 1 min, 
water, ethanol) and counterstained with 0.25% (v/v) eosin Y for 30 s. 
Finally, the slices were dehydrated using a series of alcohol solutions and 
mounted. Images were acquired using a Panoramic 250 Flash III digital 
slide scanner (3DHistech Ltd.) and analyzed using Panoramic Viewer 
software (3DHistech Ltd.). 
2.18. Statistical analysis 
Curve-fitting and statistical analysis was performed using GraphPad 
Prism 5.03 software (GraphPad Software Inc.) and SPSS statistics 22 
(IBM). Unless indicated otherwise, all results are presented as mean ±
SEM. Survival curves were analyzed by log-rank Mantel-Cox analysis. 
Body weight was compared using linear mixed model analysis. Differ-
ences between groups were tested with one- or two-way ANOVA anal-
ysis and appropriate post hoc analysis as indicated in the figure legends. 
T.J.J. Schirris et al.                                                                                                                                                                                                                             
BBA - Molecular Basis of Disease 1867 (2021) 166062
7
2.19. Key resources table  
3. Results 
3.1. Increased cholesterol biogenesis in CI-deficient fibroblasts associates 
with cellular NAD(P)H levels 
CI-deficient patient and control-specific metabolic models were 
constructed using the EXAMO algorithm [17] by integrating previously 
generated gene expression data of primary skin fibroblasts of five pa-
tients and their age- and sex-matched controls [19] (Supplementary 
Table A.1). Comparison of these models resulted in 126 reactions 
predicted to be exclusively active in patient fibroblasts and, therefore, 
expected to have largest relevance to the disease state (Supplementary 
Table B.1, Fig. 1B). Next, we selected these pathways which consume 
most electrons and consequently are expected to most effectively reduce 
harmful cellular NAD(PH) levels. This resulted in 14 pathways involved 
in lipogenesis and 28 in the biosynthesis of cholesterol and its de-
rivatives (Fig. 1B–C). 
Although both pathways consume considerable amounts of NADPH, 
lipogenesis utilizes more ATP. Considering the reduced ability to pro-
duce ATP in a CI-deficient condition the cholesterol biosynthesis is more 
likely to correct the high NAD(P)H levels, as compared to lipogenesis. In 
line with a compensatory role for the cholesterol biosynthesis, 
Reagent or resource Source Identifier 
Chemicals, peptides, and recombinant proteins 
14C-acetic acid sodium salt Perkin Elmer Cat # NEC08H 
Adenosine diphosphate sodium salt Sigma Aldrich Cat # A2754 
Adenosine triphosphate magnesium salt Sigma Aldrich Cat # A9187 
All-trans retinoic acid Sigma Aldrich Cat # R2625 
Antimycin A Sigma Aldrich Cat # A8674 
Apolipoprotein A-I Merck Millipore Cat # 178452 
Bezafibrate Sigma Aldrich Cat # B7273 
Calcium chloride Sigma Aldrich Cat # 22,350-6 
Clofibric acid (referred to as clofibrate) Sigma Aldrich Cat # 90323 
Cholesterol Sigma Aldrich Cat # C8667 
Coenzyme Q1 Sigma Aldrich Cat # C7956 
Cytochrome c Sigma Aldrich Cat # C2506 
4,4′-Diisothiocyanotostilbene-2,2′-disulfonic acid Sigma Aldrich Cat # D3514 
Decylubiquinone Enzo Life Sciences Cat # BML-CM115 
D-Glucose Sigma-Aldrich Cat # G7021 
Dimethylformamide Merck Cat # 28.02.02 
Fenofibrate Sigma Aldrich Cat # 49562-28-9 
Filipin III Sigma Aldrich Cat # F4767 
Gemfibrozil Sigma Aldrich Cat # G9518 
GW6471 Cayman Chemical Company Cat # 11697 
HEPES Sigma Aldrich Cat # H3375 
Heparin sodium salt Sigma Aldrich Cat # H3393 
Hoechst 33342 Thermo Fisher Scientific Cat # H1399 
[1,2-3H(N)]-cholesterol Perkin Elmer Cat # NET139 
Lactate dehydrogenase Roche Cat # 10127230001 
L-Alanine Sigma Aldrich Cat # 05129 
L-Aspartic acid sodium salt Sigma Aldrich Cat # A6683 
Lovastatin hydroxyacid sodium salt Toronto Research Chemicals Inc. Cat # L472250 
Magnesium chloride Merck Cat # 1.05833.0250 
L-Malic acid Sigma Aldrich Cat # M1000 
NADH Roche Cat # 10107735001 
Oligomycin Sigma Aldrich Cat # O4876 
2-Oxoglutaric acid Sigma Aldrich Cat # K3752 
Palmitoyl-L-carnitine Sigma Aldrich Cat # 61251 
Piericidin A Santa Cruz Biotechnology Cat # SC-202287 
Pyridoxal-5′-phosphate Sigma Aldrich Cat # P9255 
Potassium chloride Merck Cat # 1.04936.1000 
Rotenone Sigma Aldrich Cat # R8875 
Sodium butyrate Sigma Aldrich Cat # 10,341-0 
Sodium chloride Sigma Aldrich Cat # 31434 
Sodium succinate Sigma Aldrich Cat # S2378 
Sulphuric acid Merck Cat # 1.00731.1000 
Tetramethylrhodamine methyl ester Thermo Fisher Scientific Cat # T668 
TO-901317 Sigma Aldrich Cat # 575310 
Tris(hydroxymethyl)aminomethane Thermo Fisher Scientific Cat # 15504-020 
Vanillin Sigma Aldrich Cat # V1104  
Critical commercial assays 
Amplex® Red cholesterol assay kit Life Technologies Cat # A12216  
Experimental models: organisms/strains 
Primary cells: Healthy control-derived skin fibroblasts Radboud Center for Mitochondrial Medicine Biobank N/A 
Primary cells: CI-deficient patient-derived skin fibroblasts Radboud Center for Mitochondrial Medicine Biobank N/A 
Mice: Ndufs4− /− (Ndufs4tm1.1Rpa) Dr. Richard Palmiter N/A   
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utilization (e.g. bile acid and sterol biosynthesis) and efflux expression of 
various genes of these pathways was increased CI-deficient patients 
compared to healthy controls (Supplementary Fig. A.1A–C). Next, we 
further explored whether this could indeed compensate for the disease 
phenotype by measuring NAD(P)H levels in fibroblasts of the patient 
with lowest residual CI activity and poorest survival (P6613) and its 
matched control (C6855) (Supplementary Table A.1), with or without 
24-hour treatment with the HMG-CoA reductase (i.e. the rate-limiting 
step of the cholesterol biosynthesis) inhibitor lovastatin. In line with 
previous observations [6], total cellular NAD(P)H levels were signifi-
cantly increased in patient fibroblasts (Fig. 1D, Supplementary 
Fig. A.2A–B). Inhibition of cholesterol biosynthesis by lovastatin resul-
ted in a significantly higher increase of cellular NAD(P)H levels in the 
patient cells (Fig. 1E), which was not due to an inhibition of OXPHOS 
Fig. 2. Fibrate-induced cholesterol efflux and biosynthesis decreases cellular NAD(P)H levels in CI-deficient cells via PPAR-α-dependent upregulation of ABCA1. 
(A–B) Cellular NAD(P)H levels were determined after treatment for 48 h with gemfibrozil (100 μM) of CI-inhibited (i.e. using piericidin A) HeLa cells (n ≥ 148 
individual cells analyzed in n = 3 independent experiments). (C) Apolipoprotein A-I (apoA-I)-supported cellular cholesterol efflux was determined after treatment for 
48 h with gemfibrozil (100 μM) of CI-inhibited HeLa cells loaded with [3H]-cholesterol and expressed as the percentage of all radioactively labelled cholesterol (i.e. 
present in both cellular and medium fractions). (D–E) Cellular de novo cholesterol synthesis flux was determined by the formation of radiolabeled (14C) cholesterol 
from 14C-acetate. 14C-cholesterol levels were determined after 24-hour treatment with lovastatin hydroxyacid ( , 5 μM) or gemfibrozil ( , 100 μM) in (D) cellular and 
(E) extracellular fractions. (F–G) To study the effect of fibrates on NAD(P)H levels, (F) control and patient fibroblasts (normalized to C5120 VEH (93 ± 5 AU) were 
treated for 24 h with (■) or without ( ) gemfibrozil (100 μM, 24-hour) with or without DIDS ( , 50 μM), or GW-6471 ( , 10 μM), and (G) after TO-901317 ( ) or all- 
trans retinoic acid (ATRA, ); n ≥ 29 cells in each experiment (n = 3). Data are presented as means ± SEM. (B–C) ###p < 0.001 to compare inhibitor vs vehicle 
differences or *p < 0.05; **p < 0.01; ***p < 0.001 to compare treatment effects, by two-way ANOVA (I: inhibitor (i.e. piericidin A); T: treatment; T*I: treatmen-
t*inhibitor interaction) with Tukey’s post hoc analysis. (D, E, F, G) *p < 0.05; **p < 0.01; ***p < 0.001 to evaluate treatment effects, by one-way ANOVA with 
Dunnett’s (D, E) or Bonferroni’s (F, G) post hoc analysis. 
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complex activity (Supplementary Fig. A.3A–B) [24]. 
To further investigate the relation between cholesterol biosynthesis 
and cellular NAD(P)H pools we induced CI-deficiency in HeLa cells with 
piericidin A (PA), as recently described [8]. In accordance with previous 
studies, we could demonstrate increased total cellular NAD(P)H levels in 
these cells as a consequence of the reduced NADH oxidation by CI 
(Fig. 1F, Supplementary Fig. A.2C–D). These levels were elevated to a 
similar extent as observed in CI-deficient patient fibroblasts (Fig. 1D). 
Interestingly, lovastatin mildly decreased NAD(P)H levels in control 
HeLa cells, which may align by previous observations that lovastatin 
exposure of cancerous cell lines can inhibit their glucose uptake and 
glycolytic rates [35]. The mild lovastatin-induced reduction in NAD(P)H 
could be explained by the cytosolic NADH autofluorescence signal that 
heavily depends on the glycolytic NAD(P)H production [36]. This idea is 
supported by the absence of such an effect of lovastatin in healthy 
control fibroblasts, which rely more on oxidative metabolism [37]. 
Importantly, in PA-treated HeLa cells, inhibition of cholesterol biosyn-
thesis by lovastatin resulted in a significantly higher increase in cellular 
NAD(P)H, as compared to their untreated counterparts (Fig. 1F–G), 
which supports the idea that, compared to healthy control cells, CI- 
deficient cells have a greater dependence on cholesterol biosynthesis 
to maintain NAD(P)H levels. 
Although these results substantiate the relevance of cholesterol 
biosynthesis for patient cells, endogenous stimulation of this pathway, 
as inferred from the gene expression data in the context of the metabolic 
model, does not fully compensate the disease phenotype. Furthermore, 
total cholesterol content of patient cells was not different from control 
cells (Fig. 1H–J), indicating a tight regulation of cellular cholesterol 
levels. We therefore explored pharmacological strategies to further 
enhance cholesterol biosynthesis via stimulation of its cellular efflux. 
3.2. Pharmacological stimulation of ABCA1-dependent cholesterol efflux 
decreases cellular NAD(P)H levels and normalizes cellular growth rates 
Fibrates stimulate cellular cholesterol extrusion by increasing 
plasma membrane expression of the ATP-binding cassette subfamily A1 
(ABCA1) efflux transporter through activation of peroxisome 
proliferator-activated receptor alpha (PPAR-α) [38] (Fig. 2A). In line 
with our hypothesis that increased cholesterol efflux will stimulate 
NADPH consumption by the cholesterol biosynthesis, cellular NAD(P)H 
levels in CI-inhibited HeLa cells were normalized to control levels upon 
24-hour treatment with gemfibrozil, a fibrate commonly used to treat 
hypercholesterolemia (Fig. 2B). To investigate whether this effect was 
accompanied by an increased cellular cholesterol efflux we first loaded 
cells with radio-labelled cholesterol, after with the apolipoprotein (apo) 
A-I-supported cellular cholesterol efflux was allowed to occur as 
described previously [20]. In line with our hypothesis, gemfibrozil 
increased the cholesterol efflux rates (Fig. 2C), which confirms that 
gemfibrozil acted via ABCA1, as apo A-I specifically interacts with 
ABCA1 [20]. To investigate whether the increased efflux indeed leads to 
an increased cholesterol biosynthesis, we determined the de novo 
cholesterol biosynthesis flux (Fig. 2D–E). Treatment of HeLa cells with 
lovastatin resulted in decreased de novo synthesized cellular cholesterol 
(Fig. 2D). Although the higher cholesterol efflux upon gemfibrozil 
treatment increases the total extracellular cholesterol concentration, 
extracellular concentration of newly synthesized cholesterol only tented 
to be increased, albeit this was not statistically significant. It has to be 
noted that we observed a low signal-to-noise ratio in this assay, which 
led to an increased deviation of the experimental data (Fig. 2E). Taken 
together, the NAD(P)H-lowering effect of gemfibrozil seems to depend 
on an increased cholesterol efflux and biosynthesis leading to enhanced 
cellular NADPH consumption. 
Gemfibrozil could also reduce the increased cellular NAD(P)H levels 
in patient fibroblasts (P6613) to control levels upon 24-hour treatment 
(Fig. 2F), without altering these levels in control (C6855 and C5120) 
fibroblasts. Interestingly, we observed a decrease in NAD(P)H levels 
upon treatment with gemfibrozil in control HeLa cells. This difference 
between cell types may be explained by variations in the metabolic 
phenotype, where fibroblasts have a more oxidative metabolism [37] 
and HeLa cells have a more glycolytic phenotype. Therefore, more 
cytosolic NAD(P)H could have been available for the cholesterol 
biosynthesis to be used upon stimulation of the efflux by gemfibrozil. 
Combined with the notion that the cytosolic NAD(P)H autofluorescence 
signal heavily depends on the glycolytic NADH production [36], this 
could explain the decreased NAD(P)H levels in control HeLa cells upon 
gemfibrozil treatment. Inhibition of ABCA1 or PPAR-α, by DIDS and 
GW-6471 (Fig. 2A), respectively, completely abolished the gemfibrozil- 
induced decrease in NAD(P)H levels in patient fibroblasts, whereas they 
increased NAD(P)H levels in control cells (Fig. 2F). 
PPAR-α forms heterodimers with the retinoid X (RXR) or the liver X 
(LXR) receptor, and stimulation of these receptors with all-trans retinoic 
acid (ATRA) and TO-901317, respectively, virtually normalized the 
level of NAD(P)H in patient fibroblasts, whereas ATRA slightly but 
significantly decreased this level in control fibroblasts (Fig. 2G). This 
confirms the role of PPAR-α and ABCA1 in the mechanism underlying 
the gemfibrozil-induced normalization of cellular NAD(P)H levels in CI 
deficiency. 
Next, we evaluated the dose-dependent characteristics of the 
gemfibrozil-induced decrease in NAD(P)H levels in patient fibroblasts 
(Fig. 3A) and found a maximal normalizing effect around its EC50 value 
for PPAR-α (193 μM; [39]), further supporting the involvement of the 
PPAR-α/LXR/ABCA1 axis in these effects. To strengthen the role of 
PPAR-α, we also evaluated three other PPAR-α agonists (i.e. clofibrate, 
fenofibrate, and bezafibrate [39]), which essentially gave the same 
result (Fig. 3B-D). However, at the highest concentration used, clofibrate 
and bezafibrate increased NAD(P)H levels in one of the control cells 
(C6855) (Fig. 3B and D). Similarly to gemfibrozil, a maximal normal-
izing effect was observed around their EC50 values for PPAR-α (i.e. 
clofibrate 55 μM, fenofibrate 30 μM, bezafibrate: 50 μM). Since stimu-
lation of cholesterol biosynthesis lowers reductive stress, it can be ex-
pected to beneficially affect overall cell function. Indeed, gemfibrozil 
ameliorated the impaired growth of patient fibroblast cell line P6613 
(Fig. 3E–G) and even more potently of line P7898 (Fig. 3H). On the other 
hand, no significant effect on cell growth was observed in P6173 and 
P5866 fibroblasts (Fig. 3I–J). Together, these results support our hy-
pothesis that increasing cholesterol biosynthesis provides a therapeutic 
target to counteract the deteriorating effects of CI deficiency. 
3.3. Cholesterol efflux stimulation increases lifespan and motor function 
of Ndufs4− /− mice accompanied by stimulation of macrophage cholesterol 
efflux 
Subsequently, we investigated whether fibrates could also have a 
beneficial effect in vivo in Ndufs4− /− mice (mixed 129/Sv: C57BL6 
background), a validated model for CI-deficiency phenotypically 
mimicking Leigh syndrome [27]. Treatment with fenofibrate (100 
mg⋅kg− 1⋅day− 1, i.p.), which has favorable physicochemical properties (e. 
g. enhanced solubility) compared to other fibrates, extended the median 
survival from postnatal day (PD) 45 to PD 49, with the longest-lived 
mouse surviving 58 days (Fig. 4A). 
Up to PD 35 no differences in bodyweight were observed (Fig. 4B). 
Fenofibrate significantly increased the ability of Ndufs4− /− mice to 
complete a walking session at higher ages (Fig. 4C). As muscle weakness 
and involuntary movements are among the most burdensome clinical 
symptoms in CI-deficient patients [40], we examined motor function in 
more detail. Fenofibrate did not restore the increased run duration or 
decreased paw pressure in Ndufs4− /− mice (Fig. 4D–E). Next, we 
investigated the various types of gait support (Fig. 4F). Wildtype and 
Ndufs4− /− mice mainly rely on diagonal support, which is impaired in 
Ndufs4− /− mice and not corrected by fenofibrate (Fig. 4F–G). Increased 
support on either hind or front paws (i.e. girdle support) was restored 
(Fig. 4H), but fenofibrate could not correct the reliance on single, lateral, 
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three or four paw support (Fig. 4I–L). This suggests that the increased 
overall walking ability is not due to an increased coordination or paw 
pressure, but other gait determinants not investigated in this study. 
In vivo cellular effects of fibrate treatment were investigated by 
measuring cholesterol efflux rates in freshly isolated peritoneal macro-
phages (Fig. 4M–N). Total unsupported cholesterol efflux (i.e. without 
cholesterol acceptor proteins) was increased in untreated Ndufs4− /−
mice, in line with a compensatory role of this pathway in CI deficiency, 
and was, as in wildtype mice, further increased by fenofibrate (Fig. 4M). 
Moreover, fenofibrate increased apoA-I-supported cholesterol efflux in 
these cells (Fig. 4N). This is indicative for the involvement of ABCA1, in 
accordance with our findings in CI-deficient patient fibroblasts 
(Fig. 2E–G). Fenofibrate did also elevate plasma cholesterol levels in 
both wildtype and Ndufs4− /− mice (Fig. 4O), which can be explained by 
an increased efflux of cholesterol into the systemic circulation. In line 
with our model predictions, bile cholesterol content was increased in 
untreated Ndufs4− /− mice (Fig. 4P), which is indicative of an increased 
systematic cholesterol efflux (i.e. reverse cholesterol transport, RCT). 
However, bile cholesterol levels were not further increased in 
fenofibrate-treated Ndufs4− /− mice, whereas they were increased in 
wildtype mice after fenofibrate treatment (Fig. 4P). This may potentially 
be explained by saturation of biliary cholesterol efflux [41,42], which 
Fig. 3. Fibrates dose-dependently decrease cellular NAD(P)H levels and attenuate cell growth defects in CI-deficient fibroblasts. Dose-dependent effects of (A) 
gemfibrozil, (B) clofibrate, (C) fenofibrate, or (D) bezafibrate treatment on NAD(P)H levels after incubation for 24 h in control and patient fibroblasts (normalized to 
C5120 vehicle (VEH) (55 ± 3 AU), n ≥ 21 cells in each experiment (n = 3)). (E–J) Cellular doubling times of gemfibrozil-treated fibroblasts of (E–F) controls and CI- 
deficient patients (G) P6613, (H) P7898, (I) P6173, and (J) P5866. Grey lines indicate the dose-response curve top and bottom. Data are presented as means ± SEM. 
(A–D) ##p < 0.01 compared to C5120 control levels or *p < 0.05; **p < 0.01; ***p < 0.001 to evaluate treatment effects, by one-way ANOVA with Dunnett’s post hoc 
analysis. (E–J) a,b*p < 0.05; a,b**p < 0.01, a,b***p < 0.001; (G–J) compared to control (a:C5120, b:C6855) VEH levels, by one-way ANOVA with Dunnett’s post hoc 
analysis. Span (G–H) was tested to be significantly non-zero. 
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Fig. 4. Fibrate treatment improves life span and motor function in Ndufs4− /− mice accompanied by stimulation of cholesterol efflux. (A) Survival curves and of 
Ndufs4− /− mice treated intraperitoneally with 100 mg⋅kg bodyweight− 1⋅day− 1 fenofibrate ( ) or vehicle control (■) from postnatal day (PD) 20 onwards. (B) 
Bodyweight was assessed in wildtype and Ndufs4− /− mice with or without fenofibrate treatment (see legend in panel for color coding). (C–L) Motor function analysis 
included (C) the percentage of mice that successfully completed a walking session, (D) run duration, and (E) paw pressure and (F) Wildtype vehicle composition of 
the various types of support. (G–L) Percentage of (G) diagonal, (H) girdle, (I) single, (J) lateral, (K) three paw, and (L) four paw support. (M–N) Cellular cholesterol 
efflux from peritoneal macrophages; (M) unsupported and (N) apoA-I-supported cholesterol efflux was determined and expressed as the percentage of all radio-
actively labelled control (i.e. present in both cellular and medium fraction). (O) Plasma and (P) bile cholesterol levels were normalized to wildtype vehicle control 
(plasma 1.9 ± 0.1 mM; bile 1.3 ± 0.3 mM). Data are presented as means ± SEM; n = 23 vehicle-treated animals (n = 13 wildtype, n = 10 Ndufs4− /− ) n = 16 
fenofibrate-treated animals (n = 8 wildtype, n = 8 Ndufs4− /− ). (A, C) Survival plot differences were analyzed by Mantel-Cox tests. (B) Body weight was compared up 
to PD 35 using linear mixed model analysis (D, E, G–O) #p < 0.05, ###p < 0.001 to compare genotype vehicle differences or *p < 0.05, **p < 0.01, to compare 
treatment effects, by two-way ANOVA (G: genotype; T: treatment; T*G: treatment*genotype interaction) with Bonferroni’s post hoc analysis. 
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could already have taken place in Ndufs4− /− mice, but not wildtype, 
mice. 
Previously observed beneficial effects of bezafibrate on mitochon-
drial disease pathology have been explained by PGC-1α-dependent 
upregulation of fatty-acid β-oxidation and increased mitochondrial mass 
[43–50]. In contrast, we observed no significant changes in fatty-acid- 
driven respiration were observed in control or CI-deficient fibroblasts, 
or in muscle fibers from wildtype or Ndufs4− /− mice (Supplementary 
Fig. A.4A–B). Moreover, gemfibrozil treatment did not result in detect-
able changes in mitochondrial mass in control or patient fibroblasts 
(Supplementary Fig. A.4C–D). These findings support that stimulation of 
cholesterol efflux and consequent acceleration of cholesterol biosyn-
thesis is the most relevant beneficial effect of fibrates in CI-deficiency. 
Finally, PGC-1α and PPARγ activation are likely related to the pre-
viously observed hepatotoxic effects of bezafibrate in mice [44,48]. 
Liver weight was increased with fenofibrate (Supplementary Fig. A.5A), 
accompanied by elevated plasma ALAT levels (Supplementary 
Fig. A.5B). However, fenofibrate did not detectably increase plasma 
ASAT levels or total hepatic lipid content (Supplementary Fig. A.5C–D). 
Upon histological examination, fenofibrate displayed some small focal 
lesions in wildtype and Ndufs4− /− mice (Supplementary Fig. A.5E), 
although more diffuse lesions were observed in Ndufs4− /− mice (Sup-
plementary Fig. A.5F). Overall, hepatotoxicity by fenofibrate appeared 
to be mild as compared to the results described for bezafibrate, which 
may be attributed to its greater PPAR-α specificity. 
4. Discussion 
Using an integrative computational and experimental approach, we 
were able to identify cholesterol biosynthesis as an important compo-
nent in compensating the impaired redox state due to CI-deficiency. The 
beneficial effects of fibrates in CI-deficient patient fibroblasts is in 
agreement with the previously observed favorable effects of bezafibrate 
in several mouse models of cytochrome c oxidase (COX) or CIV defi-
ciency, as reviewed previously [44,49], and short-term beneficial effects 
recently observed after bezafibrate treatment of patients with mito-
chondrial myopathies [47]. Although bezafibrate was not beneficial in 
all mouse models, overexpression of PGC-1α increased COX activity and 
mitochondrial biogenesis in all cases. Apparently, PGC-1α is activated 
through PPAR in bezafibrate-sensitive models. 
Additional studies using alternative models also explained the posi-
tive effects of PPAR-α stimulation by an increased PGC-1α expression, 
leading to increases in OXPHOS capacity, fatty acid oxidation and 
mitochondrial mass [44,46]. We could, however, not demonstrate an 
effect on any of these pathways, which argues against an involvement of 
the PPAR-PGC-1α pathway in CI-deficient patient fibroblast. This has led 
to the idea that the mode of action of fibrates could be beneficial for 
mitochondrial disease by stimulating multiple metabolic pathways, of 
which the cholesterol synthesis may be most relevant for CI-deficiency. 
However, in none of these studies the effect on cholesterol biosyn-
thesis or efflux was investigated. Our study is, to the best of our 
knowledge, the first to demonstrate that fenofibrate treatment of 
Ndufs4− /− CI-deficient mice induced an increased cellular cholesterol 
efflux. These effects could be associated with improved survival and 
motor function, which is in line with the beneficial effects of fibrates 
previously observed in mitochondrial disease models [45,46]. In addi-
tion, the improved motor function illustrates the clinical relevance of 
our results, as recent results have suggested that this is a valid outcome 
measure for patients with an OXPHOS deficiency [40,51]. 
The improved motor function could be associated with a reduced 
brain lesions characteristic for the disease phenotype, as also observed 
in a previous study where we investigated the effects of the ROS-redox 
modulator KH176 in Ndufs4− /− mice [31]. Combined with the notion 
that the Ndufs4− /− phenotype relies mainly on a declined CNS function, 
this warrants further investigation of the effects of fenofibrate on 
neuronal cholesterol efflux, NAD(P)H levels and characteristic brain 
lesions. Although fibrates have a limited brain permeability [53,54], we 
have previously demonstrated that clofibrate does reach pharmacolog-
ically relevant levels in the brain of Ndufs4− /− mice [55]. We therefore 
argued that the effects observed on cholesterol efflux in peritoneal 
macrophages and the absence of an effect on mitochondrial fatty acid 
oxidation in muscles will also translate to brain tissue. 
The use of more potent NAD(P)H-lowering fibrates (i.e. gemfibrozil 
and clofibrate) may be associated with a more effective treatment of 
mitochondrial disease with a better balance between benefit and risk of 
liver injury. Clinical application of bezafibrate is expected to be limited 
because of its potent hepatotoxicity, which was previously observed in 
mice with late-onset mitochondrial myopathy [44]. We observed minor 
alterations in liver histology in fenofibrate-treated mice, and liver 
weight was increased 1.9-fold, as compared to a more than two-fold 
increase in previous studies showing overt liver hepatotoxicity upon 
bezafibrate treatment [44,48,49]. These effects could be due to the 
differences in PPAR-agonist potency, but are more likely explained by 
the high PPAR-α specificity of fenofibrate as compared to a pan-agonist 
(α, δ, γ) like bezafibrate [39]. 
We could also demonstrate a beneficial effect of fibrate treatment on 
the cellular growth rates of two out of four tested CI-deficient patient 
fibroblasts. These results are in line with the previously observed 
beneficial effects of lowered cellular NADH levels when mitochondrial 
function is decreased [7,8,9]. Remarkably, these two fibroblast cell lines 
(P6613 and P7898) were derived from the most short-lived patients 
studied (Supplementary Table A.1). This may suggest that these patients 
had not increased their cellular cholesterol efflux to adapt to the disease 
state, whereas this may have been the case in the longer-lived patients 
(P6173 and P5866). 
The novel link between cholesterol synthesis and cellular redox state 
in CI-deficiency could also provide novel insights into the pathophysi-
ological mechanisms of other diseases, like inborn errors of sterol 
metabolism, in which a decreased cholesterol synthesis could as well be 
expected to increase NAD(P)H levels [52]. Via the activity of NADPH 
oxidases this could lead to an increased ROS generation [10,11], even-
tually contributing to cellular damage and the observed disease 
phenotype. Further studies are, however, needed to determine whether 
NAD(P)H levels are indeed increased and whether these increased levels 
lead to increased cytosolic ROS generation by NADPH oxidases. 
Although a role of NADPH oxidase-dependent ROS generation has been 
described in mitochondrial dysfunction due to loss of COX [11], it needs 
to be verified whether this pathway is also key to the increased ROS 
levels in CI deficiency. In addition to inherited metabolic diseases, this 
link we identified between cholesterol synthesis and cellular redox state 
in CI deficiency may also be of relevance to common diseases, such as 
cancer. Cholesterol biosynthesis has demonstrated to promote tumori-
genesis [56], a process which is also associated with increased ROS 
generation by NADPH oxidases [57]. It would therefore be worthwhile 
to study the putative relationship between cholesterol biosynthesis and 
ROS levels in cancer progression. 
Our work could also explain part the short-term beneficial effects 
recently observed after bezafibrate treatment of patients with mito-
chondrial myopathies [47]. Moreover, PPAR-α-targeted stimulation of 
the cholesterol production and export may prevent long-term deregu-
lation of mitochondrial fatty acid and amino acid metabolism as has 
been observed with an unspecific PPAR-agonist, like bezafibrate. 
To conclude, we demonstrate the potential of the cholesterol 
biosynthesis pathway to compensate for a disturbed cellular redox state 
in CI-deficiency. Additional pharmacological activation of this pathway 
normalized the cellular redox state and increased the lifespan and motor 
function of CI-deficient mice. Our results indicate the presence of 
compensatory biological pathways in mitochondrial dysfunction, 
thereby providing a framework to explore novel therapeutic in-
terventions for mitochondrial diseases for which currently no cure 
exists. 
Supplementary data to this article can be found online at https://doi. 
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[53] D. Deplanque, P. Gelé, O. Pétrault, I. Six, C. Furman, M. Bouly, S. Nion, B. Dupuis, 
D. Leys, J.C. Fruchart, R. Cecchelli, B. Staels, P. Duriez, R. Bordet, Peroxisome 
proliferator-activated receptor-alpha activation as a mechanism of preventive 
neuroprotection induced by chronic fenofibrate treatment, J. Neurosci. 23 (2003) 
6264–6271, https://doi.org/10.1523/JNEUROSCI.23-15-06264.2003. 
[54] M. Grabacka, P. Waligorski, A. Zapata, D.A. Blake, D. Wyczechowska, A. Wilk, 
M. Rutkowska, H. Vashistha, R. Ayyala, T. Ponnusamy, V.T. John, F. Culicchia, 
A. Wisniewska-Becker, K. Reiss, Fenofibrate subcellular distribution as a rationale 
for the intracranial delivery through biodegradable carrier, J. Physiol. Pharmacol. 
66 (2015) 233–247. 
[55] S.J.C.M. Frambach, M.A.E. van de Wal, P.H.H. van den Broek, J.A.M. Smeitink, F. 
G.M. Russel, R. de Haas, T.J.J. Schirris, Effects of clofibrate and KH176 on life span 
and motor function in mitochondrial complex I-deficient mice, Biochim. Biophys. 
Acta Mol. basis Dis. 2020 (1866) 165727, https://doi.org/10.1016/j. 
bbadis.2020.16572. 
[56] B. Huang, B. Liang Song, C. Xu, Cholesterol metabolism in cancer: mechanisms and 
therapeutic opportunities, Nat. Metab. 2 (2020) 132–141, https://doi.org/ 
10.1038/s42255-020-0174-0. 
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